share_log

Tempus AI | 10-Q: Q3 2024 Earnings Report

SEC ·  Nov 5, 2024 05:10

Summary by Futu AI

Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.
Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.